Journal article
Recommendations for permanent prostate brachytherapy with Cs-131: A consensus report from the Cesium Advisory Group
Brachytherapy, v 7(4), pp 290-296
01 Oct 2008
PMID: 18782682
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
PURPOSE: Published clinical information on the safety and efficacy 01, 13 1 CS implants is limited. We provide Consensus recommendations for Cs-131 prostate brachytherapy based on experience to date.
METHODS AND MATERIALS: T he Cesium Advisory Group (CAG) consists of experienced Cs-131 users. Recommendations are based oil three clinical trials. one of which has completed accrual and has been published in the peer reviewed literature. and combined CAG experience of more than 1200 Cs-131 implants.
RESULTS: We recommend using 1.059 cGy h(-1) U-1 as the close rate constant for the IsoRay source. The prescription for monotherapy implants is 115 Gy and when combined with 45-50 Gy external beam it is 85 Gy. Suggested individual source strength ranges from 1.6 to 2.2 U.
The release criterion for Cs-131 implants is 6 mR h(-1) at 1 m.
Cs-131 brachytherapy should be performed differently from I-125 and Pd-103 brachytherapy: source placement is further front the urethra and rectum: the prostate V-150 should be <= 45%: Sufficient margins may be obtained while limiting Source placement to the capsule or close to the capsule.
The increased dose rate may cause degradation of postimplant quantifiers due to edema. However, large Variability in the magnitude and rate Of resolution of edema make determination of the most representative postoperative imaging time impossible. The CAG recommends postimplant imaging on the day of the implant.
Recommended postimplant evaluation goals include prostate D-90 greater than the prescription dose; maintaining D-u,D-30 < 140% of the prescription dose and keeping V-r,V-100 < 0.5 cm(3).
CONCLUSION: It was the consensus of the CAG that optimal Cs-131 implants should be performed differently from those performed with I-125 or Pd-103. Guidelines have been established to allow for safe and effective delivery of Cs-131 prostate brachytherapy. (C) 2008 Published by Elsevier Inc oil behalf of American Brachytherapy society.
Metrics
Details
- Title
- Recommendations for permanent prostate brachytherapy with Cs-131: A consensus report from the Cesium Advisory Group
- Creators
- William S. Bice - College Station Medical CenterBradley R. Prestidge - UTHSCSA, San Antonio, TX USASteven M. Kurtzman - Dorothy E Schneider Canc Ctr, San Mateo, CA USASushil Beriwal - UPMC, Ctr Canc, Dept Radiat Oncol, Pittsburgh, PA USABrian J. Moran - Prostate Canc Fdn Chicago, Westmont, IL USARakesh R. Patel - Univ Wisconsin, Dept Human Oncol, Madison, WI USAMark J. Rivard - Tufts University
- Publication Details
- Brachytherapy, v 7(4), pp 290-296
- Publisher
- Elsevier
- Number of pages
- 7
- Grant note
- IsoRay Medical, Richland, WA (IsoRay)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000260402400006
- Scopus ID
- 2-s2.0-53349162245
- Other Identifier
- 991021897267404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging